Price
Target price
€56.04
€56.04
0.860%
0.48
0.860%
€56.00
23.08.24 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
Halozyme Therapeutics Inc. gained 0.860% compared to yesterday.
The stock is an absolute favorite of our community with 23 Buy predictions and no Sell predictions.
However, we have a potential of -1.86% for Halozyme Therapeutics Inc. as the target price of 55 € is below the current price of 56.04 €.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.860% | 3.893% | 9.753% | 45.031% | 65.554% | 61.778% | 270.537% |
| Ironwood Pharmaceuticals | -5.380% | 7.653% | -33.016% | -50.059% | -58.627% | -61.982% | -45.351% |
| Arrowhead Pharmaceuticals Inc. | 0.730% | 7.427% | -16.554% | -15.983% | -21.413% | -58.166% | -20.180% |
| Novocure Ltd | 0.650% | -0.770% | -6.881% | -41.606% | 12.820% | -86.008% | -80.601% |
Comments
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $60.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Morgan Stanley from $59.00 to $64.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat